Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

H S Rugo, F André, T Yamashita, H Cerda, I Toledano, S M Stemmer, J C Jurado, D Juric, I Mayer, E M Ciruelos, H Iwata, P Conte, M Campone, C Wilke, D Mills, A Lteif, M Miller, F Gaudenzi, S Loibl

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences